THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
Foundational Pharmaceutical Sciences • 3-TIER LEARNING GUIDE

Cytochrome P450 Enzymes & Transporters (P-gp/OATP): Phase I/II Metabolism & Drug Interactions

Editorial Body: THE INDIAN PHARMACIST Editorial Reference Reading Time: 10 min read Published: 2026-01-15 Last Updated: 2026-11-08 Status: Evidence-Sourced Educational Guide

1. Level 1 — Quick Learning Overview & Core Definition

Quick Concept Summary: Hepatic and intestinal Cytochrome P450 (CYP450) enzymes and membrane efflux/uptake transporters (P-glycoprotein and OATP1B1) govern the metabolic clearance of over 75% of clinically prescribed medicines. Understanding CYP inhibition (rapid onset, elevating substrate toxicity) and CYP induction (delayed transcriptional onset over 7–14 days, causing therapeutic failure) is essential for safe prescription screening.

2. Level 2 — Standard Study: Underlying Process & Major Classifications

Biotransformation occurs in two sequential or independent phases: Phase I functionalisation reactions (oxidation, reduction, hydrolysis via smooth endoplasmic reticulum heme-thiolate CYP monooxygenases requiring NADPH and O2) and Phase II conjugation reactions (glucuronidation via UGT, sulfation via SULT, acetylation via NAT2, methylation, and glutathione conjugation).

Major Pharmacological & Scientific Classifications

  • CYP3A4 / CYP3A5 (~50% of drugs): Metabolises Statins (Atorvastatin, Simvastatin), CCBs (Amlodipine), Macrolides, Cyclosporine, Tacrolimus, Apixaban, Rivaroxaban.
  • CYP2D6 (~20% of drugs, highly polymorphic; NOT inducible): Metabolises Codeine (to Morphine), Tramadol, Metoprolol, Carvedilol, Tricyclic Antidepressants, Risperidone, Tamoxifen (to Endoxifen).
  • CYP2C9: Metabolises S-Warfarin, Phenytoin, Glimepiride, Losartan, NSAIDs.
  • CYP2C19 (Polymorphic): Bioactivates Prodrug Clopidogrel; metabolises Proton Pump Inhibitors (Omeprazole, Pantoprazole), Diazepam, Voriconazole.
  • P-glycoprotein (P-gp / ABCB1) & OATP1B1: P-gp extrudes Digoxin, Dabigatran, and Loperamide; OATP1B1 mediates hepatic uptake of Statins.

3. Original Scientific Illustration (PLATE-8.4: 8.4 Hepatic Drug Metabolism: Hepatocyte CYP450 Phase I, Phase II Conjugation & Prodrug Activation)

HEPATOCYTE BIOTRANSFORMATION: PHASE I (CYP450) & PHASE II CONJUGATION Note: Extrahepatic metabolism occurs in GI enterocytes (CYP3A4), plasma pseudocholinesterase (Succinylcholine), & lungs PHASE I: FUNCTIONALISATION • Smooth ER Microsomal CYP450 Heme Enzymes • Oxidation, Hydroxylation, Dealkylation • Key Isoforms: - CYP3A4: Statins, CCBs, Macrolides - CYP2C9: S-Warfarin, Phenytoin, Glimepiride - CYP2C19: Clopidogrel (Prodrug), PPIs - CYP2D6: Codeine, Metoprolol, Risperiodone Unmasks -OH, -COOH, -NH2, -SH groups PHASE II: CONJUGATION (SYNTHETIC) • Cytosolic & ER Transferase Enzymes • Adds polar endogenous cofactor: - Glucuronidation (UGT): Morphine, Paracetamol - Sulfation (SULT): Paracetamol, Minoxidil - Acetylation (NAT2): Isoniazid, Hydralazine - Glutathione (GST): Detoxifies NAPQI Highly polar conjugate → Urine / Bile excretion PRODRUG ACTIVATION & METABOLITES Inactive Prodrug → Active Drug: • Enalapril / Ramipril → Enalaprilat / Ramiprilat • Clopidogrel (CYP2C19) → Active Thiol • Levodopa (AADC) → Dopamine Toxic Reactive Metabolite: • Paracetamol (CYP2E1) → NAPQI (Antidote: NAC) • Cyclophosphamide → Acrolein (Antidote: Mesna) CYP450 ENZYME INHIBITION (Rapid Onset: Hours) • Inhibitors: Clarithromycin, Itraconazole, Ritonavir, Ciprofloxacin, Valproate • Effect: ↓ Clearance of active substrate → ↑ Plasma levels & Toxicity Exception: Inhibiting CYP2C19 (Omeprazole) ↓ Clopidogrel activation CYP450 ENZYME INDUCTION (Transcriptional: 7–14 Days) • Inducers: Rifampicin, Phenytoin, Carbamazepine, Phenobarbital • Effect: ↑ CYP synthesis → ↑ Substrate metabolism → Therapeutic Failure NACO Rule: Rifampicin requires doubling Dolutegravir to 50 mg BD
Figure 8.4: Hepatocyte Phase I functionalisation (Cytochrome P450 microsomal mixed-function oxidase system) and Phase II conjugation reactions, illustrating active metabolite formation, prodrug bioactivation, and clinical CYP inhibition/induction. Note: Extrahepatic metabolism also occurs in intestinal mucosa, plasma esterases, lungs, and kidneys.
Diagram Walkthrough: Hepatic biotransformation converts lipophilic xenobiotics into polar, ionised, water-soluble derivatives that resist renal tubular reabsorption. Phase I reactions (oxidation, reduction, hydrolysis) mediated by microsomal Cytochrome P450 (CYP3A4/5 ~50%, CYP2D6 ~20%, CYP2C9/2C19 ~20%, CYP1A2) introduce or unmask a polar functional group (-OH, -NH2, -COOH). Phase II reactions conjugate an endogenous hydrophilic moiety — glucuronic acid (via UGT1A1/2B7), sulfate (SULT), acetate (NAT2), or glutathione (GST) — onto the parent drug or Phase I metabolite. While most metabolism inactivates drugs, prodrugs require enzymatic bioactivation (e.g., Enalapril to Enalaprilat via CES1; Clopidogrel to active thiol via CYP2C19; Codeine to Morphine via CYP2D6). Extrahepatic metabolism is equally vital for drugs like remifentanil and esmolol (plasma/red-cell esterases).

4. Level 3 — Advanced Clinical, Pharmacokinetic & Regulatory Reference

Prodrug vs Active Substrate Interaction Reversal: When a drug is administered in its active form (e.g., S-Warfarin or Simvastatin), inhibiting its metabolising enzyme (e.g., with Metronidazole/Fluconazole on CYP2C9, or Clarithromycin/Itraconazole on CYP3A4) decreases clearance and causes severe toxicity (bleeding or rhabdomyolysis). Conversely, when a medicine is an inactive PRODRUG requiring CYP bioactivation — such as Clopidogrel (via CYP2C19), Codeine (via CYP2D6), or Tamoxifen (via CYP2D6) — co-administering an enzyme inhibitor (such as Omeprazole/Esomeprazole with Clopidogrel, or Paroxetine/Fluoxetine with Tamoxifen) blocks active metabolite formation and causes therapeutic failure (stent thrombosis or breast cancer relapse).

5. Common Misunderstandings & Clinical Pitfalls

Common Misunderstanding: Assuming all Proton Pump Inhibitors inhibit CYP2C19 equally when co-prescribed with Clopidogrel. Omeprazole and Esomeprazole are strong CYP2C19 inhibitors and should be avoided with Clopidogrel; Pantoprazole or Rabeprazole have minimal CYP2C19 inhibition and are preferred when gastroprotection is required alongside Clopidogrel.

6. Key Takeaways, Related Medicine Monographs & Calculators

Key Study & Practice Takeaways:
  • Memorise key CYP Inhibitors ('SICKFACES.COM': Sodium valproate, Isoniazid, Cimetidine, Ketoconazole/Itraconazole, Fluconazole, Acute alcohol, Clarithromycin/Ciprofloxacin, Erythromycin, Sulfonamides, Grapefruit juice, Omeprazole, Metronidazole).
  • Memorise key CYP Inducers ('CRAP GPS': Carbamazepine, Rifampicin, Chronic Alcohol, Phenytoin, Griseofulvin, Phenobarbital, St. John's Wort).
  • Remember that CYP2D6 is genetically polymorphic (poor vs ultra-rapid metabolisers) and is NOT inducible by classic enzyme inducers.

Related Medicine Monographs

💊 Atorvastatin [3.11] →💊 Phenytoin Sodium [11.13] →💊 Azithromycin [8.3] → ⚖️ Compare Medicines →

Related Clinical Calculators

🧮 Corrected Calcium & Phenytoin (Sheiner-Tozer) →🧮 Creatinine Clearance (Cockcroft-Gault) →

7. Authoritative Medical & Regulatory References

  1. Indian Pharmacopoeia Commission (IPC) & CDSCO: Indian Pharmacopoeia (IP 2022) & National List of Essential Medicines (NLEM 2022), Ministry of Health and Family Welfare, Government of India (https://ipc.gov.in/ & https://cdsco.gov.in/).
  2. NCBI Bookshelf / National Library of Medicine: StatPearls Pharmacology, Physiology & Clinical Therapeutics Compendia (https://www.ncbi.nlm.nih.gov/books/).
  3. DailyMed (US National Library of Medicine): Official FDA Prescribing Information & Clinical Pharmacology Labelling (US Jurisdiction Reference) (https://dailymed.nlm.nih.gov/dailymed/).
  4. MedlinePlus, NHS Health Information, Cleveland Clinic Health Library & National Institute on Aging (NIA): Structured patient education and clinical communication references (MedlinePlus • NHS • Cleveland Clinic • NIA).